ASX Share rice
Sat 08 Aug 2020 - 04:07:am (Sydney)

SDX Share Price

SIENNA CANCER DIAGNOSTICS LIMITEDSDXPharmaceuticals, Biotechnology & Life Sciences

SDX Company Information

Name:

Sienna Cancer Diagnostics Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

Small Technologies Cluster Scoresby VIC Australia 3179

Phone:

61 3 8288 2141

CEO, MD & Director:

Mr. Carl S. Stubbings

CFO, Company Sec. & Exec. Director:

Mr. Tony Di Pietro

Company Overview:

Sienna Cancer Diagnostics Limited, a medical technology company, identifies, develops, and commercializes cancer-related in-vitro diagnostic tests for use in pathology laboratories worldwide. The company offers SCD-A7, an anti-human telomerase reverse transcriptase antibody for the detection of the biomarker for cancer. It also provides SIEN-NET technology, a sample preparation platform to enhance the performance of liquid biopsy diagnostic assays. The company has a research collaboration agreement with Minomic International Ltd to develop a proprietary test for the early detection of pancreatic cancer. The company was formerly known as Sienna Capital Ltd and changed its name to Sienna Cancer Diagnostics Limited in 2006. Sienna Cancer Diagnostics Limited was founded in 2002 and is headquartered in Scoresby, Australia.

SDX Share Price Information

Shares Issued:

395.13M

Dividend Yield:

%

Revenue (TTM):

$1M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.011

Operating Margin (TTM):

$-3.33

Return On Assets (TTM):

$-0.20

Return On Equity (TTM):

$-0.36

Quarterly Revenue Growth (YOY):

-0.056

Gross Profit(TTM):

$0.99M

Diluted Earnings Per Share (TTM):

$-0.011

SDX CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-633,709

Change To Liabilities:

$-108,151

Total Cashflow From Investing Activities:

$-633,709

Net Income:

$-2,699,586

Total Cash From Operating Activities:

$-2,485,239

Depreciation:

$21.56K

Change To Inventory:

$-1,090

Change To Account Receivables:

$35.28K

Sale Purchase Of Stock:

$-331,724

Capital Expenditures:

$633.71K

SDX Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-2,699,586

Net Income:

$-2,699,586

Gross Profit:

$478.95K

Operating Income:

$-3,352,020

Other Operating Expenses:

$9.53K

Total Revenue:

$531.25K

Total Operating Expenses:

$3.83M

Cost Of Revenue:

$52.30K

SDX Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$4.12M

Total Liabilities:

$394.90K

Total Stockholder Equity:

$8.58M

Total Assets:

$8.98M

Common Stock:

$27.30M

Retained Earnings:

$-19,014,301

Other Liabilities:

$65.51K

Other Assets:

$1.95M

Cash:

$4.47M

Total Current Liabilities:

$329.39K

Property - Plant & Equipment:

$88.17K

Net Tangible Assets:

$6.41M

Total Current Assets:

$4.77M

Net Receivables:

$277.88K

Short-Term Investments:

$4.21M

Inventory:

$17.01K

Accounts Payable:

$147.67K

Non Currrent Assets (Other):

$4.21M

Short-Term Investments:

$4.21

Non Current Liabilities Total:

$65.51K

SDX Share Price History

SDX News

25 Feb, 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
16 Dec, 2019
Anyone researching Sienna Cancer Diagnostics Limited (ASX:SDX) might want to consider the historical volatility of the...
17 Oct, 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...